- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.02. | AbbVie and Xilio announce immunotherapy partnership worth over $2.1bn | 10 | PMLiVE | ||
| 13.02. | AbbVie and Xilio to collaborate on antibody-based immunotherapies | 6 | Pharmaceutical Technology | ||
| 12.02. | Why Is Nano-Cap Cancer-Focused Xilio Therapeutics Stock Trading Over 100% On Wednesday? | 3 | Benzinga.com | ||
| 12.02. | AbbVie signs heavily backloaded $2.1B Xilio biobucks pact in Big Pharma's latest T-cell engager deal | 12 | FierceBiotech | ||
| 12.02. | AbbVie, Xilio Hook up | 4 | Baystreet.ca | ||
| XILIO THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 12.02. | AbbVie and Xilio Therapeutics announce collaboration and option agreement | 7 | Seeking Alpha | ||
| 12.02. | AbbVie, Xilio Partner To Develop Novel Tumor-Activated Immunotherapies; Stock Up In Pre-market | 11 | RTTNews | ||
| 12.02. | Xilio-Aktien schnellen nach Kooperationsvereinbarung mit AbbVie in die Höhe | 4 | Investing.com Deutsch | ||
| 12.02. | Xilio shares soar on AbbVie collaboration deal | 5 | Investing.com | ||
| 12.02. | AbbVie und Xilio kooperieren bei tumoraktivierten Therapien | 7 | Investing.com Deutsch | ||
| 12.02. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs | 146 | GlobeNewswire (Europe) | Also entered into collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies, including masked T cell engagers, with $52.0 million in upfront payments Extended... ► Artikel lesen | |
| 12.02. | Xilio Therapeutics, Inc.; AbbVie Inc.: AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies | 150 | GlobeNewswire (Europe) | Collaboration will combine AbbVie's oncology expertise and Xilio's proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell engagersXilio to host investor... ► Artikel lesen | |
| 12.02. | AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies | 150 | PR Newswire | Collaboration will combine AbbVie's oncology expertise and Xilio's proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell... ► Artikel lesen | |
| 12.02. | Xilio Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 03.02. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 40 | GlobeNewswire (Europe) | WALTHAM, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies... ► Artikel lesen | |
| 21.01. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal ... | 64 | GlobeNewswire (Europe) | 27% preliminary response rate observed in heavily pre-treated microsatellite stable colorectal cancer (MSS CRC) patients without liver metastases Responses were accompanied by decreases in levels... ► Artikel lesen | |
| 21.01. | Xilio Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 17.01. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 10.01. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 184 | GlobeNewswire (Europe) | WALTHAM, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies... ► Artikel lesen | |
| 19.12.24 | Gilead Sciences erwirbt Xilio Therapeutics-Aktien im Wert von 1,83 Millionen US-Dollar | 27 | Investing.com Deutsch |
Seite:
1 2 Weiter >>
38 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PALATIN TECHNOLOGIES | 0,849 | -2,53 % | Palatin Technologies Inc. Q2 Loss Decreases, Beats Estimates | WASHINGTON (dpa-AFX) - Palatin Technologies Inc. (PTN) revealed Loss for second quarter that decreased from the same period last year and beat the Street estimates.The company's earnings came... ► Artikel lesen | |
| BIOXXMED | 0,832 | -7,56 % | EQS-Adhoc: bioXXmed AG: bioXXmed beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts | EQS-Ad-hoc: bioXXmed AG / Schlagwort(e): Sonstiges
bioXXmed AG beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts
21.02.2025 / 20:29 CET/CEST
Veröffentlichung... ► Artikel lesen | |
| ORGANOVO | 0,688 | +12,97 % | Organovo, Inc.: Organovo's FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company | SAN DIEGO, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) ("Organovo" or the "Company"), a clinical stage biotechnology company focused on developing novel treatment approaches... ► Artikel lesen | |
| OCUGEN | 0,581 | -6,89 % | Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease | MALVERN, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,037 | -10,98 % | Sirona Biochem präsentiert TFC-1326 in wegweisendem Bericht von Stonegate Healthcare | 15. Januar 2025 - Vancouver, British Columbia / IRW-Press / Sirona Biochem Corp. (TSX-V: SBM) (FWB:
ZSB) (OTC: SRBCF) freut sich bekannt zu geben, dass sein innovativer Anti-Aging-Wirkstoff TFC-1326... ► Artikel lesen | |
| BIO-GATE | 0,755 | -2,58 % | EQS-News: Bio-Gate AG: Medizinisches CBD-Muskelpflege-Gel von Bio-Gate erhält in klinischer Studie Testergebnis "sehr gut" | EQS-News: Bio-Gate AG
/ Schlagwort(e): Studienergebnisse/Sonstiges
Bio-Gate AG: Medizinisches CBD-Muskelpflege-Gel von Bio-Gate erhält in klinischer Studie Testergebnis "sehr... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,866 | +10,46 % | Defence Therapeutics Inc.: Defence Closes Second Tranche of Fully Subscribed Financing Totaling $4.2 Million | Montreal, Quebec--(Newsfile Corp. - January 31, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing... ► Artikel lesen | |
| VAXART | 0,460 | -4,84 % | Oppenheimer maintains Vaxart stock Outperform amid BARDA order | ||
| BURCON NUTRASCIENCE | 0,056 | -1,07 % | Burcon NutraScience Corporation: Burcon Announces Details of $9.43 Million Rights Offering | Vancouver, British Columbia--(Newsfile Corp. - February 18, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in the development... ► Artikel lesen | |
| AFFIMED | 0,900 | -4,26 % | XFRA DIVERSE INSTRUMENTE: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCASTOR MARITIME... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 0,270 | -1,46 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring | Evaluating strategic options for iopofosine I 131 a late-stage clinical program with compelling Phase 2 data and a substantial market opportunity Focusing on advancing radiotherapeutic assets including... ► Artikel lesen | |
| IMMUNIC | 1,114 | -2,45 % | EQS-News: Immunic AG: Immunic to Participate in Scientific and Investor Conferences in March | Issuer: Immunic AG
/ Key word(s): Conference
Immunic to Participate in Scientific and Investor Conferences in March
03.03.2025 / 12:30 CET/CEST
The issuer is solely... ► Artikel lesen | |
| AIM IMMUNOTECH | 0,124 | 0,00 % | AIM ImmunoTech Inc.: AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza | Proposed study of Ampligen as a vaccine adjuvant to increase cross-reactivity to influenza strainsOCALA, Fla., Feb. 28, 2025(NYSE American: AIM) ("AIM" or the "Company") today announced that Paul Goepfert... ► Artikel lesen | |
| T2 BIOSYSTEMS | 0,119 | +3,95 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 20.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 20.02.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 20.02.2025.ISIN NameCA24703H1029 DELIVRA... ► Artikel lesen | |
| CEL-SCI | 0,310 | -1,96 % | CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer | VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) reported financial results for the fiscal year ended September 30, 2024, as well as key clinical and corporate developments.
"We... ► Artikel lesen |
XILIO THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,906 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu XILIO THERAPEUTICS INC finden Sie auf Wallstreet Online.
